Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology
Kumquat received U.S. Food and Drug Administration (FDA) clearance of the investigational new drug (IND) for its KRAS G12D inhibitor in July 2025. Under the terms of the agreement, Kumquat will receive up to $1.3 billion, including upfront, clinical and commercial milestones, and additional tiered royalties on net sales. Kumquat retains an exclusive option to negotiate for participating in profit-loss sharing in the US.
'We are constantly evaluating innovative approaches to improve outcomes for patients, focusing on areas of high unmet medical need,' said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer's Pharmaceuticals Division. 'We look forward to collaborating with Kumquat, an accomplished team of experts with deep KRAS insights. Our intent is to explore the development of a potential new treatment option for patients, while further complementing Bayer's robust early precision oncology pipeline.'
Oncogenic driver mutations, such as KRAS mutations, are changes in the DNA of genes that drive the development and growth of cancer. These mutations are often identified as key targets for cancer treatment, and their identification offers the opportunity to develop target-specific drugs. KRAS G12D mutations are found most frequently in 37 percent of pancreatic ductal adenocarcinoma (PDAC), 13 percent of colorectal cancer and 4 percent of non-small cell lung cancers. 2 PDAC is the most common type of pancreatic cancer (accounting for 85 percent of cases) and remains one of the most difficult tumors to treat, with patients having few treatment options beyond chemotherapy and the five-year survival rate being less than 10 percent. 3 Pancreatic cancer is the sixth leading cause of cancer-related death worldwide. 4 The incidence continues to rise annually, with projections indicating a 95.4 percent increase in new cases by 2050, potentially reaching a total of 998,663 new cases globally. 4
'KRAS mutations are crucial for cancer development and can be targeted with specific therapies in a more selective manner,' said Dominik Ruettinger, M.D., Ph.D., Global Head of Research and Early Development for Oncology at Bayer's Pharmaceuticals Division. 'KRAS mutations occur in nearly 25 percent of human cancers, yet the most prevalent and oncogenic KRAS (G12D) variant still lacks effective treatment options. We look forward to exploring the investigational KRAS G12D inhibitor, which targets a highly relevant signaling pathway that promotes tumor growth and survival.'
'Since pioneering the direct targeting of KRAS G12C mutation over a decade ago, we have continued to discover innovative strategies to target other KRAS mutants, including KRAS G12D,' said Yi Liu, Chief Executive Officer of Kumquat. 'Advancing our novel KRAS G12D asset into the clinic reflects our commitment to delivering durable therapies for KRAS patients suffering from deadly malignancies such as pancreatic, lung and colorectal cancers. This collaboration with Bayer validates the strength of our platform and the potential of our KRAS G12D candidate to address long-standing unmet needs in oncology. We are thrilled to collaborate with Bayer, who shares our vision and strategy for realizing the benefit of small molecule-based transformative treatments. While advancing optimally our KRAS G12D program through the clinic, this collaboration provides Kumquat the financial resources to accelerate its broader clinical pipeline for long-term value, and position Kumquat to deliver life-changing medicines and achieve sustained growth in the coming years.'
About Kumquat Biosciences
Kumquat Biosciences is a privately held drug discovery and development company committed to creating life-changing medicines for cancer patients. The company focuses on translating breakthrough science into first-in-class therapeutics. Kumquat brings together an accomplished team and distinguished scientific founder with a proven track record of innovative oncology drug discovery and development. The company launched in 2019 and was funded by OrbiMed, HSG, EcoR1, Lilly Asia Ventures, Roche Venture Fund, and Boxer Capital, and previously entered two major collaborations with Eli Lilly and Takeda. For more information, please visit www.kumquatbiosciences.com.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.
Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
ak (2025-0140e)
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
1 Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014 Nov;13(11):828-51. doi: 10.1038/nrd4389. Epub 2014 Oct 17. PMID: 25323927; PMCID: PMC4355017.
2 Herdeis L, Gerlach D, McConnell DB, Kessler D. Stopping the beating heart of cancer: KRAS reviewed. Curr Opin Struct Biol. 2021 Dec;71:136-147. doi: 10.1016/j.sbi.2021.06.013. Epub 2021 Jul 22. PMID: 34303932.
3 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021; 27(35): 5851-5889 URL: https://www.wjgnet.com/1007-9327/full/v27/i35/5851.htm
4 Leiphrakpam PD, Chowdhury S, Zhang M, Bajaj V, Dhir M, Are C. Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes. J Gastrointest Cancer. 2025 Feb 24;56(1):71. doi: 10.1007/s12029-025-01183-2. PMID: 39992560.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Clinical Trial Application Success: CMC and Regulatory Insights from the US to Europe, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights on optimizing Investigational New Drug (IND) and Clinical Trial Application (CTA) submissions through aligned chemistry, manufacturing and controls (CMC) and regulatory strategies. Attendees will learn about key CMC requirements for early-phase development and strategies to leverage accelerated CMC programs. The featured speakers will discuss EMA and FDA clinical trial authorization requirements. The speakers will also share strategies to minimize regulatory gaps when transitioning from US to EU trials. Attendees will learn about the development support provided by the FDA and EMA, requirements for the importation of the investigational drug into the EU and more. TORONTO, Aug. 15, 2025 /PRNewswire/ -- The Investigational New Drug (IND) application in the US and Clinical Trial Application (CTA) in Europe are key milestones in advancing innovative therapies to clinical development. This webinar will discuss the technical and regulatory aspects of IND and CTA submissions in the US and Europe. The speakers will explore CMC requirements, highlighting key technical challenges and practical solutions encountered during the early-phase development of both the drug substance and drug product. The speakers will also address the regulatory landscape, discussing EMA and FDA filing requirements, importation requirements for the EU and strategies for transitioning from US-based to EU-based trials. Whether it's a robust CMC strategy or a well-planned regulatory approach, both play a crucial role in enhancing the success rate and efficiency of IND submissions. Join this webinar to learn how expert perspectives from CMC and regulatory specialists can help minimize regulatory gaps, optimize timelines and streamline early-phase development. Join the featured speakers to explore: Real-world insights on overcoming CMC hurdles during IND and CTA preparation Approaches to aligning technical documentation with evolving regulatory expectations Lessons learned from supporting global submissions across the US and EU Register to gain practical insights on optimizing IND and CTA submissions through aligned CMC and regulatory strategies. Join William Lian, Director of Filing and Regulatory Affairs Office, BioDuro; and Arna Hrund Arnardóttir, PhD, Senior Consultant, DADA Consultancy, for the live webinar on Wednesday, September 3, 2025, at 10am EDT (4pm CEST/EU-Central). For more information, or to register for this event, visit Clinical Trial Application Success: CMC and Regulatory Insights from the US to Europe. ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit information about hosting a webinar visit Contact:Vera KovacevicTel: +1 (416) 977-6555 x371Email: vkovacevic@ View original content to download multimedia: SOURCE Xtalks Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's Aspirina, the #1 pain relief option in Mexico 1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic consumers, Aspirina is poised to provide an accessible and effective solution for pain relief. Bayer's Aspirina, the #1 pain relief option in Mexico, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. Share As the Hispanic population in the U.S. continues to grow, currently representing 19 percent of the population and projected to reach 28 percent by 2060, Bayer Aspirin recognizes the importance of connecting with this vibrant community. The Aspirina pain relief option resonates deeply with cultural values and family traditions of those from Mexican and Latin American descent who have been using it as a long-standing pain relief option. 'Many Hispanic communities still face inadequate access to healthcare and consumer goods. As the fastest-growing demographic group in the U.S., the Hispanic population presents a unique opportunity for Bayer. By adding Aspirina to the U.S. portfolio, which has a strong equity in LATAM, we are placing the consumer at the center of our strategy. Data shows that 70 percent of Hispanic consumers feel a strong connection to their country of origin, making it essential for brands to honor and reflect this sentiment,' said Mohamed Atef, Global Brand Lead for Aspirin at Bayer. Many U.S. consumers of Hispanic origin grew up with Bayer's Aspirina— their parents and grandparents relied on it, instilling trust and nostalgia for the brand. Due to those deep connections, Aspirina has a 99 percent awareness rate in Mexico, with 67 percent of consumers using it regularly 2. With this inclusion in the U.S. market, we invite consumers to reconnect with a product that represents reliability, familiarity and their heritage. Bayer invented modern aspirin 125 years ago, and it's the most trusted aspirin brand for pain relief in the U.S. 3 Many pain reliever brands have come and gone over the last century, but Bayer® Aspirin continues to be one of the most trusted pain brands on the market. Aspirina is available at select Walmart and Walgreens, making it easy for families to find the pain relief they know. Join us in celebrating the launch of Aspirina in the U.S. and rediscover a brand that feels like home — a trusted companion in the journey of life. For more information on Aspirina visit About Aspirina For over 125 years, Bayer® Aspirin has been a leading aspirin brand in proven pain relief. Aspirina is a powerful pain reliever and fever reducer that contains 500 mg of the active ingredient aspirin (NSAID*). It provides fast and effective multi-symptom relief of headaches, muscle pain, toothaches, menstrual pain and minor arthritis pain for adults and children over 12, when used as directed. Aspirina is coated to make it easy to swallow and is free of caffeine. *nonsteroidal anti-inflammatory drug About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 1 Based on volume sales in the last 52 weeks, via source: Grupo Knoblock/CID – Centro Integrador de Datos
Axios
2 days ago
- Axios
Off-the-shelf vaccine shows success against deadly cancers
An experimental vaccine targeting one of the most common genetic drivers of hard-to-treat pancreatic and colorectal cancers prevented their recurrence, raising hopes for an "off the shelf" treatment that can train the immune system to attack malignancies. Why it matters: If shown effective in further trials, the vaccine could become a particularly important tool in staving off the return of pancreatic cancer, which sees roughly 80% of surgically removed tumors recur within five years. What they're saying:"This was a trial all of us in the medical oncology world have been waiting for," said Tracy Proverbs-Singh, an oncologist at Hackensack Meridian's John Theurer Cancer Center. "We see these patients for five years, we see the recurrences, we have to re-treat them, and it's devastating. And after we finish chemo, there's not a lot we can do." Go deeper: The peptide vaccine targets the KRAS mutation that occurs in roughly 90% of pancreatic cancers and half of colorectal cancers. Researchers administered the shot, called ELI-002 2P, to 25 patients who'd received conventional treatments but still had small amounts of cancer left in their bodies and were at high risk of relapse. Half of patients had no relapse by 16.3 months, and median overall survival was 28.9 months — both exceeding historical norms, per the study in Nature Medicine. The greatest benefit was seen in patients who had strong T cell responses. At the 20-month mark, 17 of the 25 patients had strong immune responses with 11 of those patients having no recurrence and six having delayed recurrence. The latter successfully underwent further treatment. "All the 17 were still alive which is why we think there's optimistically, something real going on here, because that's much better than what we might have expected historically," said Zev Wainberg, co-director of the UCLA GI Oncology Program and one of the lead authors. Yes, but: Researchers do not yet understand why eight of the 23 patients did not develop a strong immune response as a result of the vaccine. Between the lines: Much of the enthusiasm around therapeutic cancer vaccines has centered on personalized mRNA technology. It is notable that researchers were able to use a non-personalized vaccine because it can be more easily developed at scale. "It's a big shot in the arm for the pancreatic cancer vaccine, which has been elusive in the context of us being able to get something that's effective in the early stages," said Madappa Kundranda, division chief for cancer medicine at Banner MD Anderson Cancer Center. Reality check: This is still a small Phase 1 trial and will require a more robust randomized controlled trial. Wainberg said the team has already completed such a trial and should have results back in 2026. What to watch: Pancreatic cancer, which has a five-year survival rate of around 13% in the U.S., could be treated very differently within the next two years as multiple new drugs targeting the same mutations are also developed.
